Patents by Inventor Xingliang ZHOU

Xingliang ZHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
    Publication number: 20230331808
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Application
    Filed: May 12, 2023
    Publication date: October 19, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
  • Chimeric molecules providing targeted costimulation for adoptive cell therapy
    Patent number: 11697677
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: July 11, 2023
    Assignee: INSTIL BIO (UK) LIMITED
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
  • MODIFIED PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USE
    Publication number: 20210040449
    Abstract: The disclosure provides a method of generating modified T cells from engineered stem cells for use in an autologous or allogeneic setting for engineered immunotherapy. The knockout of endogenous TCR or HLA expression allows for engineering of modified pluripotent stem cells that reduce or eliminate the risk of Graft versus Host Disease (GVHD), provide resistance to elimination by a recipient's T cells and NK cells, and allow for controllable T cell activity. Thus, this method allows the development of T cells with reduced immune reactivity.
    Type: Application
    Filed: February 15, 2019
    Publication date: February 11, 2021
    Inventors: Eric GSCHWENG, Rajul JAIN, Yong OUYANG, Arianne PEREZ GARCIA, Margo ROBERTS, Ruben ALVAREZ RODRIGUEZ, Drake SMITH, Xingliang ZHOU